Literature DB >> 2924448

Low-molecular-weight membrane component inhibits the metastatic phenotype of B16-F10 melanoma.

Z Keren1, S J LeGrue.   

Abstract

Treatment of the metastatic melanoma cell lines B16-F1 and B16-F10 with 1.5-2 per cent butanol elevates their experimental metastatic potential, whereas reconstitution of butanol-extracted B16 cells with crude butanol extracts decreases the number of experimentally induced lung foci. We partially purified the biologically active components from crude butanol extracts of B16-F1 by high-performance liquid chromatography and isoelectric focusing, and found the inhibitory activity (i) was in the low-molecular-weight (5-10 kDa) fraction of the chromatogram, (ii) had an isoelectric pH between 5.6 and 5.8, (iii) was distinct from a thiol-protease activity eluted from the isoelectric focusing bed at pH 4.9-5.3 and (iv) was not itself an inhibitor of serine or thiol proteases. Incubation of butanol-extracted B16-F10 cells with known inhibitors of serine, acid and thiol protease inhibitors had no effect on the experimental metastatic phenotype. Although the apparent molecular weight was low, the inhibitor(s) tended to aggregate after focusing, probably owing to the presence of carrier ampholines. Using two-dimensional gel electrophoresis, we observed slight differences between intact and butanol-extracted cells, most of them in the low-molecular-weight region. These results suggest that butanol treatment may reversibly release certain inhibitors of cell surface enzymes other than proteases, which might be involved in invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924448     DOI: 10.1007/BF01753683

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  33 in total

1.  Collagenolytic activity in malignant melanoma: physiocochemical studies.

Authors:  Y Yamanishi; E Maeyens; M K Kabbous; H Ohyama; K Hashimoto
Journal:  Cancer Res       Date:  1973-10       Impact factor: 12.701

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation by butanol extraction.

Authors:  Z Keren; S J LeGrue
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

4.  Degradation of the subendothelial matrix by tumor cells.

Authors:  W E Laug; Y A DeClerck; P A Jones
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

5.  Proteolytic enzymes in tumor metastasis. II. Collagenase type IV activity in subcellular fractions of cloned tumor cell populations.

Authors:  L Eisenbach; S Segal; M Feldman
Journal:  J Natl Cancer Inst       Date:  1985-01       Impact factor: 13.506

6.  Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.

Authors:  T Turpeenniemi-Hujanen; U P Thorgeirsson; I R Hart; S S Grant; L A Liotta
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

7.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Cathepsin B activity in B16 melanoma cells: a possible marker for metastatic potential.

Authors:  B F Sloane; K V Honn; J G Sadler; W A Turner; J J Kimpson; J D Taylor
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

Review 9.  Heparanases and tumor metastasis.

Authors:  M Nakajima; T Irimura; G L Nicolson
Journal:  J Cell Biochem       Date:  1988-02       Impact factor: 4.429

10.  Role of glycosidases in human ovarian carcinoma cell mediated degradation of subendothelial extracellular matrix.

Authors:  M J Niedbala; R Madiyalakan; K Matta; K Crickard; M Sharma; R J Bernacki
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

View more
  1 in total

Review 1.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.